Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients

MT Newswires Live07-07

Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients.

The biotech firm said that there have been no serious adverse events reported among all patients dosed to date, and that it continues to expect to present phase 2a data in Q4.

Oragenics also said it has submitted a Type B meeting request to the US Food and Drug Administration for guidance on its planned US clinical development program for ONP-002 that is intended to support an Investigational New Drug application. The company said it is aiming to submit its application in Q4.

Shares of Oragenics were up 6.3% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649938876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649938876","market":"sh","top_or_hot":-1,"title":"Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients","media":"MT Newswires Live","content":"<html><body><p> Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients.</p><p>The biotech firm said that there have been no serious adverse events reported among all patients dosed to date, and that it continues to expect to present phase 2a data in Q4.</p><p>Oragenics also said it has submitted a Type B meeting request to the US Food and Drug Administration for guidance on its planned US clinical development program for ONP-002 that is intended to support an Investigational New Drug application. The company said it is aiming to submit its application in Q4.</p><p>Shares of Oragenics were up 6.3% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOragenics Says All Three Australian Concussion Trial Sites Enrolling Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-07 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients.</p><p>The biotech firm said that there have been no serious adverse events reported among all patients dosed to date, and that it continues to expect to present phase 2a data in Q4.</p><p>Oragenics also said it has submitted a Type B meeting request to the US Food and Drug Administration for guidance on its planned US clinical development program for ONP-002 that is intended to support an Investigational New Drug application. The company said it is aiming to submit its application in Q4.</p><p>Shares of Oragenics were up 6.3% pre-bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYAU.AU","symbol_name":"Etfs S&p/asx 300 High Yield Plus Etf","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649938876","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649938876","pubTimestamp":1783429653,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oragenics  said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients.The biotech firm said that there have been no serious adverse events reported among all patients dosed to date, and that it continues to expect to present phase 2a data in Q4.Oragenics also said it has submitted a Type B meeting request to the US Food and Drug Administration for guidance on its planned US clinical development program for ONP-002 that is intended to support an Investigational New Drug application. The company said it is aiming to submit its application in Q4.Shares of Oragenics were up 6.3% pre-bell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf","BK4139":"生物科技","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","BEAR.AU":"BETASHARES AUS EQ BEAR HF","DACE.AU":"DIMENSIONAL AUST CORE EQ","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","IISV.AU":"INTELL INV SELVAL SHR FD MF","VAS.AU":"VANGUARD AUST SHARES IDX ETF","E200.AU":"SPDR S&P/ASX 200 ESG FUND","QFN.AU":"BetaShares Australian Fincls Sect ETF","GEAR.AU":"BETASHARES GEARED AUS EQTY F","QRE.AU":"BetaShares Australian Res Sect ETF","GIVE.AU":"PERPETUAL ESG AU SHR EQMF","OGEN":"Oragenics Inc.","IOZ.AU":"iShares Core S&P/ASX 200","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","XKO.AU":"标普/澳交所 300指数","STW.AU":"SPDR® S&P/ASX 200 ETF","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","EIGA.AU":"EINVEST INCOME GENERATOR FD","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)"},"translate_title":"Oragenics表示澳大利亚所有三个脑震荡试验点都招募了患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBOZ.AU":0.6,"STW.AU":0.6,"XJO.AU":1.5,"ZYAU.AU":0.6,"IISV.AU":0.6,"E200.AU":0.6,"QFN.AU":0.6,"OZF.AU":0.6,"QRE.AU":0.6,"IIGF.AU":0.6,"VAP.AU":0.6,"GIVE.AU":0.6,"XKO.AU":1.5,"IMLC.AU":0.6,"OZR.AU":0.6,"BEAR.AU":0.6,"XAO.AU":1.5,"VAS.AU":0.6,"IOZ.AU":0.6,"OGEN":1.5,"DACE.AU":0.6,"GEAR.AU":0.6,"EIGA.AU":0.6,"SLF.AU":0.6},"content_text":"Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients.The biotech firm said that there have been no serious adverse events reported among all patients dosed to date, and that it continues to expect to present phase 2a data in Q4.Oragenics also said it has submitted a Type B meeting request to the US Food and Drug Administration for guidance on its planned US clinical development program for ONP-002 that is intended to support an Investigational New Drug application. The company said it is aiming to submit its application in Q4.Shares of Oragenics were up 6.3% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649938876","isCrawlerRequest":true}